Interleukin-2 (IL-2) is the pivotal cytokine in T cell differentiation (O'Garra, 1989; Oliver, 1988) . Recombinant interleukin-2 (rIL-2) has been used in cancer treatment together with in vitro activated lymphocytes (adoptive immunotherapy) (Rosenberg et al., 1987; von Flidener et al., 1987; West et al., 1987) . IL-2 enhances the cytotoxic activity of a population of natural killer cells capable of killing tumour cells through a mechanism independent of the histocompatibility antigens (Malkovsky et al., 1988) .
IL-2 acts via interaction with high affinity, cell bound receptors (IL-2R) (Wang & Smith, 1987) . The light chain of these heterodimeric receptors is identified by monoclonal antibodies as the Tac antigen (Uchiyama et al., 1981) .
A soluble form of IL-2 receptors (sIL-2R), which retains the ability to bind IL-2, is released by activated lymphoid cells. (Pizzolo et al., 1987a, b) , acquired immunodeficiencies (Kloster et al., 1987) , organ transplantation (Colvin et al., 1987) and granulomatous disorders (Lawrence et al., 1987) . Scattered data on various solid neoplasia indicate an increase of sIL-2R (Rovelli et al., 1988) , while a study aimed to breast cancer did not find any significant variation of this parameter (Nelson et al., 1987 We studied 43 caucasian patients (33 males and 10 females, age 63 ± 10 years) affected with small cell lung cancer (nine patients), and non-small cell lung cancer (34 patients) of different hystological type (squamous carcinoma, adenocarcinoma, unclassified carcinoma). The patients included in this study did not previously receive any treatment. Co-existing infections were excluded on the basis of clinical criteria along with the absence of leukocytosis and positive cultures of body fluids. Clinical staging was possible in 26 patients and was performed according to the TNM classification of the UICC (1978) . Levels of sIL-2R were determined with the commercial Cell Free IL-2R Test Kit (T Cell Science, Cambridge, MA, USA). Forty-one healthy individuals, sex and age matched with the patients, served as the reference group. Statistical evaluation was performed by Kruskal-Wallis analysis of variance, and the significances of differences between groups were assessed by the non-parametric test of Mann-Whitney and Wilcoxon.
Median values of sIL-2R were significantly higher (P <0.0001) in patients (821 U ml-') than controls (495 U ml-') ( Figure 1) . No significant differences were found within different histological types, nor within different disease stages (Figure 2 ), between metastatic and nonmetastatic patients (stage 1, 2, 3 versus 4). This study demonstrates that sIL-2R are elevated in lung cancer. The lack of correlation with either histological type or disease stage suggests that this finding is not directly dependant on the tumour cells, but is more likely to be an aspect of the immunological response elicited by the neoplasia. The reason for the absence of such a correlation is not unequivocal. Constitutional differences in synthesis and/or catabolism may influence the serum levels of sIL-2R in different subjects. Longitudinal studies, now in progress on patients moving from one stage to another, may at least in part answer these questions. If we accept the hypothesis that sIL-2R act as a physiological modulator of IL-2 action it will be interesting to consider their value in predicting the effectiveness of rIL-2 in cancer treatment.
